BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28779631)

  • 1. Diagnostic characteristics of lethal prostate cancer.
    Helgstrand JT; Røder MA; Klemann N; Toft BG; Brasso K; Vainer B; Iversen P
    Eur J Cancer; 2017 Oct; 84():18-26. PubMed ID: 28779631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
    Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
    Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
    Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
    Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
    Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
    Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
    Heering M; Berg KD; Brasso K; Iversen P; Røder MA
    Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
    Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
    Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
    Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
    Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.
    Buzzoni C; Auvinen A; Roobol MJ; Carlsson S; Moss SM; Puliti D; de Koning HJ; Bangma CH; Denis LJ; Kwiatkowski M; Lujan M; Nelen V; Paez A; Randazzo M; Rebillard X; Tammela TL; Villers A; Hugosson J; Schröder FH; Zappa M
    Eur Urol; 2015 Nov; 68(5):885-90. PubMed ID: 25791513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry.
    Vatandoust S; Kichenadasse G; O'Callaghan M; Vincent AD; Kopsaftis T; Walsh S; Borg M; Karapetis CS; Moretti K
    BJU Int; 2018 May; 121 Suppl 3():48-54. PubMed ID: 29603585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer.
    Joniau S; Spahn M; Briganti A; Gandaglia G; Tombal B; Tosco L; Marchioro G; Hsu CY; Walz J; Kneitz B; Bader P; Frohneberg D; Tizzani A; Graefen M; van Cangh P; Karnes RJ; Montorsi F; van Poppel H; Gontero P;
    Eur Urol; 2015 Feb; 67(2):319-25. PubMed ID: 24684960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
    Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.
    Thomsen FB; Mikkelsen MK; Hansen RB; Krug AH; Glenthøj A; Stattin P; Brasso K
    Acta Oncol; 2016 Dec; 55(12):1456-1460. PubMed ID: 27333339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
    Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
    World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
    Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
    Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
    Osses DF; Remmers S; Schröder FH; van der Kwast T; Roobol MJ
    Eur Urol; 2019 Mar; 75(3):374-377. PubMed ID: 30420254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
    Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
    Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
    Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.